Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles

被引:87
作者
Kondo, E
Akatsuka, Y
Kuzushima, K
Tsujimura, K
Asakura, S
Tajima, K
Kagami, Y
Kodera, Y
Tanimoto, M
Morishima, Y
Takahashi, T
机构
[1] Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 464, Japan
[3] Japanese Red Cross Nagoya First Hosp, Dept Hematol, Nagoya, Aichi, Japan
[4] Okayama Univ, Grad Sch Med & Dent, Dept Internal Med 2, Okayama, Japan
关键词
D O I
10.1182/blood-2003-03-0824
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytomegalovirus (CMV)-specific T-cell immunity plays an important role in protection from CMV disease in immunocompromised patients. Identification of cytotoxic T-lymphocyte (CTL) epitopes is essential for monitoring T-cell immunity and also for immunotherapy. In this and previous studies, CMV-pp65-specific CTL lines were successfully generated from all of 11 CMV-seropositive healthy donors, using pp65-transduced CD40-activated B (CD40-B) cells as antigen-presenting cells. By use of enzyme-linked immunospot (ELISPOT) assays, individual CTL epitopes could be mapped with truncated forms of the pp65 gene. For human leukocyte antigen (HLA) alleles with a known binding motif, CTL epitopes within the defined regions were predicted by computer algorithm. For HLA alleles without a known binding motif (HLA-Cw*0801, -Cw*1202, and -Cw*1502), the epitopes were alternatively identified by step-by-step truncations of the pp65 gene. Through this study, a total of 14 novel CTL epitopes of CMV-pp65 were identifled. Interestingly, 3 peptides were found to be presented by 2 different HLA class I alleles or subtypes. Moreover, use of CD40-B cells pulsed with a mixture of synthetic peptides led to generation of pp65-specific CTL lines from some of seronegative donors. The study thus demonstrated an efficient strategy for identifying CTL epitopes presented by a variety of HLA alleles.
引用
收藏
页码:630 / 638
页数:9
相关论文
共 57 条
[1]   Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines [J].
Akatsuka, Y ;
Goldberg, TA ;
Kondo, E ;
Martin, EG ;
Obata, Y ;
Morishima, Y ;
Takahashi, T ;
Hansen, JA .
TISSUE ANTIGENS, 2002, 59 (06) :502-511
[2]   Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy [J].
AlexanderMiller, MA ;
Leggatt, GR ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4102-4107
[3]   Interferon-γ can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase [J].
Beninga, J ;
Rock, KL ;
Goldberg, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (30) :18734-18742
[4]   DETECTION OF HUMAN CYTOMEGALOVIRUS DNA IN PERIPHERAL-BLOOD LEUKOCYTES BY THE POLYMERASE CHAIN-REACTION [J].
BEVAN, IS ;
WALKER, MR ;
DAW, RA .
TRANSFUSION, 1993, 33 (09) :783-784
[5]   Estimating the precursor frequency of naive antigen-specific CD8 T cells [J].
Blattman, JN ;
Antia, R ;
Sourdive, DJD ;
Wang, XC ;
Kaech, SM ;
Murali-Krishna, K ;
Altman, JD ;
Ahmed, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (05) :657-664
[6]   Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].
Boeckh, M ;
Leisenring, W ;
Riddell, SR ;
Bowden, RA ;
Huang, ML ;
Myerson, D ;
Stevens-Ayers, T ;
Flowers, MED ;
Cunningham, T ;
Corey, L .
BLOOD, 2003, 101 (02) :407-414
[7]   Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide [J].
Craiu, A ;
Akoplan, T ;
Goldberg, A ;
Rock, KL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10850-10855
[8]   Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation [J].
Cwynarski, K ;
Ainsworth, J ;
Cobbold, M ;
Wagner, S ;
Mahendra, P ;
Apperley, J ;
Goldman, J ;
Craddock, C ;
Moss, PAH .
BLOOD, 2001, 97 (05) :1232-1240
[9]   Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection [J].
Diamond, DJ ;
York, J ;
Sun, JY ;
Wright, CL ;
Forman, SJ .
BLOOD, 1997, 90 (05) :1751-1767
[10]   Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy [J].
Einsele, H ;
Roosnek, E ;
Rufer, N ;
Sinzger, C ;
Riegler, S ;
Löffler, J ;
Grigoleit, U ;
Moris, A ;
Rammensee, HG ;
Kanz, L ;
Kleihauer, A ;
Frank, F ;
Jahn, G ;
Hebart, H .
BLOOD, 2002, 99 (11) :3916-3922